Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy Study Comparing 0.9 g and 1.25 g Estrogel With Placebo for Vasomotor Symptoms and Vulvar and Vaginal Atrophy

This study has been completed.
Solvay Pharmaceuticals
Information provided by (Responsible Party):
ASCEND Therapeutics Identifier:
First received: September 8, 2005
Last updated: July 11, 2013
Last verified: July 2013

This study is intended to establish the lowest effective dose of EstroGel® for the treatment of vasomotor symptoms associated with menopause.

Condition Intervention Phase
Postmenopausal Symptoms
Drug: Estradiol
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Efficacy Study Comparing 0.9 g and 1.25 g EstroGel® 0.03% Doses With Placebo in the Treatment of Vasomotor Symptoms and Vulvar and Vaginal Atrophy Associated With Menopause

Resource links provided by NLM:

Further study details as provided by ASCEND Therapeutics:


Ages Eligible for Study:   45 Years to 65 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Women 45-65 years
  • naturally or surgically postmenopausal
  • experiencing hot flushes

Exclusion Criteria:

  • hypersensitivity to estrogen replacement therapy
  • pregnancy or lactating
  • abnormal PAP smear
  • history/suspected cervical, uterine, adrenal, pituitary, breast or ovarian malignancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00160173

  Show 109 Study Locations
Sponsors and Collaborators
ASCEND Therapeutics
Solvay Pharmaceuticals
Study Director: Global Clinical Director Solvay Solvay Pharmaceuticals
  More Information

No publications provided

Responsible Party: ASCEND Therapeutics Identifier: NCT00160173     History of Changes
Other Study ID Numbers: S166.4.003
Study First Received: September 8, 2005
Last Updated: July 11, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by ASCEND Therapeutics:
Post menopausal vasomotor symptoms processed this record on November 25, 2014